$558.9 million in 2026 is projected to grow to $1.151 billion by 2036, with demand tied to child-focused immune formulas that fit daily routines and offer clear age-based dosing.
35.7% of U.S. youth aged 0 to 19 already use supplements, the report said, supporting demand for products that balance evidence, taste and dosage clarity to win repeat purchases.
Gummies are forecast to lead formats with a 41.5% share in 2026, while beta-glucan is expected to top ingredients at 34.6% as brands favor familiar immune-support actives.
The 4 to 12 age band is projected to hold a 46.3% share, online retail 32.8%, and supplement brands 57.4%, reflecting school-age routines, comparison shopping and direct control of product messaging.
UAE, Saudi Arabia and South Korea are seen growing fastest at 9.3%, 8.8% and 8.4%, though tighter claims review, import files and dosage rules remain key constraints.